Clinical Trial Details

Trial ID: L0130
Source ID: NCT02781584
Associated Drug: Selonsertib
Title: Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
Acronym: --
Status: Completed
Study Results: Has Results
Results: https://ClinicalTrials.gov/show/NCT02781584/results
Conditions: Nonalcoholic Steatohepatitis (NASH)|Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: Drug: SEL|Drug: FIR|Drug: CILO|Drug: FENO|Drug: VAS
Outcome Measures: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events|Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events|Percentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities
Sponsor/Collaborators: Gilead Sciences
Gender: All
Age: 18 Years and older ?? (Adult, Older Adult)
Phases: Phase 2
Enrollment: 220
Study Type: Interventional
Study Designs: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Start Date: June 13, 2016
Completion Date: December 17, 2020
Results First Posted: February 2, 2022
Last Update Posted: March 16, 2022
Locations: Arizona Liver Health, Chandler, Arizona, United States|Altman Clinical and Translational Research Clinic, La Jolla, California, United States|Ruane Clinical Research Group Inc., Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford Hospital and Clinics (SHC), Stanford, California, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Delta Research Partners, LLC, Bastrop, Louisiana, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Pinnacle Clinical Research, PLLC, Live Oak, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Pinnacle Clinical Research, PLLC, San Antonio, Texas, United States|Auckland Clinical Studies Ltd, Auckland, New Zealand
URL: https://ClinicalTrials.gov/show/NCT02781584

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D326 Selonsertib Chemical drug DB14916 MAP3K5 inhibitor; ASK1 inhibitor Anti-oxidative stress; Anticancer agent Failed in clinical trials Details
D078 Cilofexor Chemical drug DB15168 FXR agonist Enhance lipid metabolism Under clinical trials Details
D136 Firsocostat Chemical drug DB16166 ACC inhibitor Enhance lipid metabolism Under clinical trials Details